Multi-modal treatment for neonatal HIE: hypothermia and dendrimer nanotherapy
Document text
Principal Investigator: MARY A WILSON Organization: HUGO W. MOSER RES INST KENNEDY KRIEGER Fiscal Year: 2019 Award: $175,337 Funding agency: Eunice Kennedy Shriver National Institute of Child Health and Human Development No abstract provided Terms: <0-11 years old><Acquired brain injury><Acute><Address><Age><Animal Model><Animal Models and Related Studies><Anti-inflammatory><Asphyxia Neonatorum><Astrocytes><Astrocytus><Astroglia><Autism><Autistic Disorder><Behavioral><Brain><Brain Hypoxia-Ischemia><Brain Injuries><Brain Nervous System><Cell Communication and Signaling><Cell Death><Cell Signaling><Cerebral Palsy><Child><Child Development Disorders><Child Youth><Childhood><Children (0-21)><Chronic><Combined Modality Therapy><Complementary therapies><Complementary treatment><Consumption><Control Animal><Cy5><Cysteine><Data><Dendrimers><Dendritic Compounds><Dendrons><Developmental Disabilities><Disease><Disorder><Drug Delivery><Drug Delivery Systems><Drugs><Early Infantile Autism><Encephalon><Equilibrium><Exposure to><Female><Glutathione><Goals><Half-Cystine><Histologic><Histologically><Hortega cell><Human><Hydroxyl><Hydroxyl Radical><Hypothermia><IDDRC><IDDRP><Immune><Immunes><Immunoglobulin Enhancer-Binding Protein><Incidence><Infant><Infantile Autism><Inflammation><Inflammatory><Inflammatory Response><Injury><Intellectual and Developmental Disabilities Research Centers><Intervention><Intervention Strategies><Intracellular Communication and Signaling><Intravenous><KST gene><KST protein><Kanner's Syndrome><L-Cysteine><Label><Lipid Peroxidation><MRDD Research Center><MRDDRC><Measures><Medication><Mental Retardation and Developmental Disabilities Research Centers><Mice><Mice Mammals><Microglia><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Murine><Mus><NF-kB><NF-kappa B><NF-kappaB><NFKB><Nanotechnology><Neonatal><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><Neurodevelopmental Disability><Neurodevelopmental Disorder><Neurological Development Disorder><Neurons><Nuclear Factor kappa B><Nuclear Transcription Factor NF-kB><Nuclear Translocation><Outcome><Oxidation-Reduction><P53><PI4><Pathway interactions><Perinatal Hypoxia><Perinatal Hypoxic-Ischemic Encephalopathy><Perinatal anoxic ischemic brain injury><Pharmaceutic Preparations><Pharmaceutical Preparations><Phosphorylation><Prevention><Protease Inhibitor 4><Protein Phosphorylation><RIP1><RIP3><RIPK1><RIPK1 gene><RIPK3><RIPK3 gene><Receptor-Interacting Protein><Receptor-Interacting Protein 3><Receptor-Interacting Serine/Threonine Kinase 1><Receptor-Interacting Serine/Threonine Protein Kinase 3><Redox><Research><Rewarming><SERPINA4><SERPINA4 gene><Seizures><Signal Transduction><Signal Transduction Systems><Signaling><TP53><TP53 gene><TRP53><Therapeutic><Tissue Kallikrein Inhibitor><Transcription Factor NF-kB><Translational Research><Translational Science><Treatment Efficacy><Tumor Protein p53 Gene><Work><ages><antiinflammatory><astrocytic glia><autism spectrum disorder><autistic spectrum disorder><balance><balance function><biological signal transduction><birth asphyxia><brain damage><brain-injured><cellular targeting><children><childrens'><combination therapy><combined modality treatment><combined treatment><cyanine dye 5><cytokine><disability><drug/agent><gamma-L-Glu-L-Cys-Gly><gamma-L-Glutamyl-L-Cysteinylglycine><gitter cell><hypoxia ischemia><hypoxic ischemic encephalopathy><improved><injured><intervention efficacy><interventional strategy><kallistatin><kappa B Enhancer Binding Protein><male><mesoglia><microglial cell><microgliocyte><model of animal><model organism><mortality><mouse model><multi-modal therapy><multi-modal treatment><murine model><nano particle><nano tech><nano technology><nano therapeutic><nano therapy><nano-sized particle><nano-technological><nanoparticle><nanosized particle><nanotech><nanotechnological><nanotherapeutic><nanotherapy><natural hypothermia><necrocytosis><neonatal HIE><neonatal hypoxia-ischemia><neonatal hypoxic-ischemic brain injury><neonate><neurobehavioral><neuronal><neuroprotection><nuclear factor kappa beta><oxidation reduction reaction><p53 Genes><pathway><pediatric><perinatal asphyxia><perivascular glial cell><post-natal asphyxia><postnatal><postnatal asphyxia><site targeted delivery><targeted delivery><therapeutic efficacy><therapeutically effective><therapy efficacy><translation research><treatment effect><treatment strategy><youngster>